Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
Journal of Medical Economics|January 7, 2018
Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populationsEytan M Stein, Gaetano Bonifacio, Dominick Latremouille-Viau, et al.Journal of Managed Care & Specialty Pharmacy|March 25, 2015
Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured populationJeffrey R Curtis, Benjamin Chastek, Laura Becker, et al.Health and Quality of Life Outcomes|September 23, 2018
Assessing utility values for treatment-related health states of acute myeloid leukemia in the United StatesEytan M Stein, Min Yang, Annie Guerin, et al.The American Journal of Managed Care|March 13, 2008
Care coordination to increase referrals to smoking cessation telephone counseling: a demonstration projectScott E Sherman, Nancy Takahashi, Preety Kalra, et al.The Annals of Pharmacotherapy|August 17, 2006
Physicians' perceived knowledge of and responsibility for managing patients' out-of-pocket costs for prescription drugsWilliam H Shrank, Steven M Asch, George J Joseph, et al.Advances in Therapy|August 30, 2018
Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United StatesKaren Seiter, Dominick Latremouille-Viau, Annie Guerin, et al.Journal of Medical Economics|April 24, 2014
Use of a validated algorithm to estimate the annual cost of effective biologic treatment for rheumatoid arthritisJeffrey R Curtis, Vernon F Schabert, Jason Yeaw, et al.The American Journal of Managed Care|September 12, 2006
Physicians' perceptions of relevant prescription drug costs: do costs to the individual patient or to the population matter most?William H Shrank, George J Joseph, Niteesh K Choudhry, et al.Clinical Therapeutics|July 12, 2014
Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claimsJeffrey R Curtis, Vernon F Schabert, David J Harrison, et al.The Journal of Rheumatology|August 17, 2014
Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritisGrant W Cannon, Scott L DuVall, Candace L Haroldsen, et al.Pageof 3